Special Issue "Diabetic Liver Disease"

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (20 August 2020).

Special Issue Editor

Dr. Yoshio Sumida
Website1 Website2
Guest Editor
1: Department of Hepatology and Pancreatology, Aichi Medical University of Medicine, Nagakute, Aichi, Japan
2: Japan Strategic Medical Administration Research Center (J-SMARC), Nagoya, Aichi, Japan
Interests: nonalcoholic steatohepatitis; oxidative stress; hepatic fibrosis; diabetes mellitus; liver cirrhosis; hepatocellular carcinoma
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Nonalcoholic fatty liver disease (NAFLD) which is the most prevalent chronic liver disease, is associated with type 2 diabetes (T2D). Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can progress to cirrhosis, hepatocellular carcinoma (HCC), and hepatic failure. Liver-related mortality is the 3rd leading cause in T2D patients. NASH can be called “diabetic liver disease (DLD)”. Accumulating evidence shows that PNPLA3 SNP is associated with fibrosis progression or HCC development. This Special Issue will include papers investigating the pathological mechanisms of T2DM and liver diseases such as NASH, and diagnostics using new biomarkers. Furthermore, experimental in vitro and in vivo studies and clinical studies examining potential new approaches to attenuate DLD are welcome. The journals IJMS and Life will jointly be publishing a Special Issue covering the topic “Diabetic Liver Disease”. This Special Issue welcomes original research and review papers.

Suggested Topics:

  1. Mechanisms of insulin resistance and hepatic steatosis/fibrosis;
  2. The role of SNPs with disease severity in DLD;
  3. The role of microbiota in DLD;
  4. Endocrine system in DLD;
  5. Antifibrotic agents in DLD;
  6. How can we stop HCC development?
  7. Mechanisms of cardiac/renal disease and DLD;
  8. Mechanisms of extrahepatic neoplasms development in DLD;
  9. Novel antidiabetic drugs in DLD;
  10. Noninvasive tests (NITs) of hepatic fibrosis in DLD.

Assoc. Prof. Dr. Yoshio Sumida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nonalcoholic fatty liver disease
  • Hepatocellular carcinoma
  • Nonalcoholic steatohepatitis
  • Type 2 diabetes
  • Hepatic fibrosis
  • Liver cirrhosis
  • PNPLA3

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop